Lifecell Corp-LIFC reiterate Buy following bus tour@NEED Needham does not believe Bard (BCR) is getting traction with Collamend or Allomax in the initial launches and they expect LIFC to launch a xenograft, bringing possible upside to 2007 estimates. :